Update on the management of alcoholic steatohepatitis

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 2, 2013, Pages 189-197

  Stickel, Felix ^a,b   Seitz, Helmut K ^c  

^a Klinik Beau Site   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acetaldehyde; Corticosteroids; Endotoxins; Enteral nutrition; Liver failure; Liver transplantation; Pentoxifylline; Tumor necrosis factor

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALCOHOL DEHYDROGENASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYTOCHROME P450 2E1; ETANERCEPT; INFLIXIMAB; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FATTY LIVER; HEPATITIS; HISTOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; PATHOGENESIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ACETYLCYSTEINE; ADRENAL CORTEX HORMONES; ALCOHOL ABSTINENCE; ANIMALS; ENTERAL NUTRITION; FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PENTOXIFYLLINE; TREATMENT OUTCOME;

EID: 84879163758     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011;7:661-671.
2. Welch C, Harrison D, Short A, Rowan K. The increasing burden of alcoholic liver disease on United Kingdom critical care units: secondary analysis of a high quality clinical database. J Health Serv Res Policy 2008;13(Suppl 2):40-44.
3. Liang W, Chikritzhs T, Pascal R, Binns CW. Mortality rate of alcoholic liver disease and risk of hospitalization for alcoholic liver cirrhosis, alcoholic hepatitis and alcoholic liver failure in Australia between 1993 and 2005. Intern Med J 2011;41:34-41.
4. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007;46:827-839.
5. Trabut JB, Plat A, Thepot V, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008;43:559-563.
6. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111.
7. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011;45:714-719.
8. Sandahl TD, Jepsen P Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol 2011;54:760-764.
9. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: metaanalysis of individual patient data. Gut 2011;60:255-260.
10. Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92:208-214.
11. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-1029.
12. McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res 2011;35:815-820.
13. Antar R, Wong P Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol 2012;26:463-467.
14. Hamberg KJ, Carstensen B, Sorensen TI, Eghoje K. Accuracy of clinical diagnosis of cirrhosis among alcohol-abusing men. J Clin Epidemiol 1996;49:1295-1301.
15. Lieber CS. Alcohol: its metabolism and interaction with nutrients. Ann Rev Nutr 2000;20:395-430.
16. Klatsky AL, Chartier D, Udaltsova N, et al. Alcohol drinking and risk of hospitalization for heart failure with and without associated coronary artery disease. Am J Cardiol 2005;96:346-351.
17. Cervoni JP, Thévenot T, Weil D, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012;56:1299-1304.
18. Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541-548.
19. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336-339.
20. Martín-Llahí M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140:488-496.
21. Ginès P, Schrier RW Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
22. Salerno F, Gerbes A, Gines P Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.
23. Crawford JM. Histologic findings in alcoholic liver disease. Clin Liver Dis 2012;16:699-716.
24. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32:3-13.
25. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010;51:307-328.
26. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420.
27. Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010;16:966-972.
28. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (Fibroscan) irrespectively of fibrosis. Hepatology 2008;48:1718-1723.
29. Kubes P Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012;143:1158-1172.
30. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006;387:349-360.
31. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004;34:9-19.
32. Albano E. New concepts in the pathogenesis of alcoholic liver disease. Expert Rev Gastroenterol Hepatol 2008;2:749-759.
33. Naveau S, Abella A, Raynard B, et al. Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. Am J Gastroenterol 2001;96:3361-3367.
34. Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007;47:277-283.
35. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J Hepatol 2006;44:784-790.
36. Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxins. Am J Physiol 1998;275:G605-611.
37. Tilg H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
38. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
39. Colmenero J, Bataller R, Sancho-Bru P et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007;132:687-697.
40. Argiles JM, Lopez-Soriano FJ, Busquets S. Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012;17:253-262.
41. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
42. Dunn W Jamil H, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353-358.
43. Srikureja W Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700-706.
44. Dominguez M, Rincón D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103:2747-2756.
45. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174-1179.
46. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348-1354.
47. Sandahl TD, Jepsen P, Ott P, Vilstrup H. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand J Gastroenterol 2011;46:1127-1132.
48. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
49. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-1081.
50. Stickel, Hoehn B, Schuppan D, Seitz HK. Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003;18: 357-373.
51. Mendenhall CL, Roselle GA, Gartside P, Moritz T Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995;19:635-641.
52. Cabré E, Rodriguez-Iglesias P, Caballeria J, et al. Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32:36-42.
53. Plauth M, Cabré E, Riggio O, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006;25:285-294.
54. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with metaanalyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27:1167-1178.
55. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: metaanalysis of individual patient data. Gut 2011;60:255-260.
56. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448-455.
57. Tilg H, Jalan R, Kaser A, et al. Anti-tumour necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-425.
58. Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:1182-1187.
59. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-1397.
60. Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open-label trial. J Hepatol 2009;50:584-591.
61. Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-260.
62. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcohol hepatitis. Gastroenterology 2008;135:1953-1960.
63. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009;(4): CD007339.
64. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013 Mar 13. [Epub ahead of print].
65. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010;138:1755-1762.
66. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991;324:1852-1857.
67. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-864.
68. Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117-1122.
69. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781-1789.
70. Lucey MR. Is liver transplantation an appropriate treatment for acute alcoholic hepatitis? J Hepatol 2002;36:829-831.
71. Neuberger J. Public and professional attitudes to transplanting alcoholic patients. Liver Transpl 2007;13:S65-68.
72. Wells JT, Said A, Agni R, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007;13:1728-1735.
73. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790-1800.
74. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012;55:1398-1405.